1
|
Mousavifar L, Roy R. Recent development in the design of small 'drug-like' and nanoscale glycomimetics against Escherichia coli infections. Drug Discov Today 2021; 26:2124-2137. [PMID: 33667654 DOI: 10.1016/j.drudis.2021.02.025] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 02/19/2021] [Accepted: 02/24/2021] [Indexed: 12/25/2022]
Abstract
Glycoconjugates are involved in several pathological processes. Glycomimetics that can favorably emulate complex carbohydrate structures, while competing with natural ligands as inhibitors, are gaining considerable attention owing to their improved hydrolytic stability, binding affinity, and pharmacokinetic (PK) properties. Of particular interest are the families of α-d-mannopyranoside analogs, which can be used as inhibitors against adherent invasive Escherichia coli infections. Bacterial resistance to modern antibiotics triggers the search for new alternative antibacterial strategies that are less susceptible to acquiring resistance. In this review, we highlight recent progress in the chemical syntheses of this family of compounds, one of which having reached clinical trials against Crohn's disease (CD).
Collapse
Affiliation(s)
- Leila Mousavifar
- Department of Chemistry, Université du Québec à Montréal, PO Box 8888, Succ. Centre-Ville, Montréal, QC H3C 3P8, Canada
| | - René Roy
- Department of Chemistry, Université du Québec à Montréal, PO Box 8888, Succ. Centre-Ville, Montréal, QC H3C 3P8, Canada; INRS - Institut Armand-Frappier, Université du Québec, 531 Boul. des Prairies, Laval, QC H7V 1B7, Canada.
| |
Collapse
|
2
|
Elamary RB, Albarakaty FM, Salem WM. Efficacy of Acacia nilotica aqueous extract in treating biofilm-forming and multidrug resistant uropathogens isolated from patients with UTI syndrome. Sci Rep 2020; 10:11125. [PMID: 32636429 PMCID: PMC7341837 DOI: 10.1038/s41598-020-67732-w] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2019] [Accepted: 06/10/2020] [Indexed: 01/27/2023] Open
Abstract
Escherichia coli is the dominant bacterial cause of UTI among the uropathogens in both developed and developing countries. This study is to investigate the effect of Acacia nilotica aqueous extract on the survival and biofilm of isolated pathogens to reduce UTIs diseases. A total of 170 urine samples were collected from Luxor general hospital and private medical analysis laboratories in Luxor providence, Egypt. Samples were screened for the incidence of uropathogens by biochemical tests, antibiotics susceptibility, detection of virulence, and antibiotic-resistant genes by multiplex PCR, biofilm formation, and time-killing assay. Escherichia coli is by far the most prevalent causative agent with the percentage of 73.7% followed by Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeuroginosa, and Acinetobacter baumanii. Isolates were multidrug-resistant containing blaTEM, blaSHV, blaCTX, qnrs, and aac(3)-Ia resistant genes. All isolates were sensitive to 15-16.7 mg ml-1 of Acacia nilotica aqueous extract. Time killing assay confirmed the bactericidal effect of the extract over time (20-24 h). A high percentage of 3-Cyclohexane-1-Carboxaldehyde, 2,6,6-trimethyl (23.5%); á-Selinene (15.12%); Oleic Acid (14.52%); Globulol (11.35%) were detected among 19 bioactive phytochemical compounds in the aqueous extract of A. nilotica over the GC-mass spectra analysis. The plant extract reduced significantly the biofilm activity of E. coli, K. pneumoniae, P. mirabilis, and P. aeuroginosa by 62.6, 59. 03, 48.9 and 39.2%, respectively. The challenge to improve the production of A. nilotica phytochemicals is considered a very low price for the return.
Collapse
Affiliation(s)
- Rokaia B Elamary
- Department of Botany and Microbiology, Faculty of Science, South Valley University, Qena, 83523, Egypt
| | - Fawziah M Albarakaty
- Department of Biology, College of Applied Sciences, Umm Al Qura University, Makkah Al Moukarramh, Saudi Arabia
- Department of Biology, College of Science, Princess Nourah Bint Abdul Rahman University, Riyadh, Saudi Arabia
| | - Wesam M Salem
- Department of Botany and Microbiology, Faculty of Science, South Valley University, Qena, 83523, Egypt.
| |
Collapse
|
3
|
Subramani B, Shantamurthy CD, Maru P, Belekar MA, Mardhekar S, Shanmugam D, Kikkeri R. Demystifying a hexuronic acid ligand that recognizes Toxoplasma gondii and blocks its invasion into host cells. Org Biomol Chem 2019; 17:4535-4542. [PMID: 30994681 DOI: 10.1039/c9ob00744j] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Toxoplasma gondii is a ubiquitous eukaryotic pathogen responsible for toxoplasmosis in humans and animals. This parasite is an obligate intracellular pathogen and actively invades susceptible host cells, a process which is mediated by specific receptor-ligand interactions. Here, we have identified an unnatural 2,4-disulfated d-glucuronic acid (Di-S-GlcA), a hexuronic acid composed of heparin/heparan sulfate, as a potential carbohydrate ligand that can selectively bind to T. gondii parasites. More importantly, the gelatin conjugated Di-S-GlcA multivalent probe displayed strong inhibition of parasite entry into host cells. These results open perspective for the future use of Di-S-GlcA epitopes in biomedical applications against toxoplasmosis.
Collapse
Affiliation(s)
- Balamurugan Subramani
- Indian Institute of Science Education and Research, Dr. Homi Bhabha Road, Pune, 411008, India.
| | | | | | | | | | | | | |
Collapse
|
4
|
de Ruyck J, Roos G, Krammer EM, Prévost M, Lensink MF, Bouckaert J. Molecular Mechanisms of Drug Action: X-ray Crystallography at the Basis of Structure-based and Ligand-based Drug Design. BIOPHYSICAL TECHNIQUES IN DRUG DISCOVERY 2017. [DOI: 10.1039/9781788010016-00067] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Biological systems are recognized for their complexity and diversity and yet we sometimes manage to cure disease via the administration of small chemical drug molecules. At first, active ingredients were found accidentally and at that time there did not seem a need to understand the molecular mechanism of drug functioning. However, the urge to develop new drugs, the discovery of multipurpose characteristics of some drugs, and the necessity to remove unwanted secondary drug effects, incited the pharmaceutical sector to rationalize drug design. This did not deliver success in the years directly following its conception, but it drove the evolution of biochemical and biophysical techniques to enable the characterization of molecular mechanisms of drug action. Functional and structural data generated by biochemists and structural biologists became a valuable input for computational biologists, chemists and bioinformaticians who could extrapolate in silico, based on variations in the structural aspects of the drug molecules and their target. This opened up new avenues with much improved predictive power because of a clearer perception of the role and impact of structural elements in the intrinsic affinity and specificity of the drug for its target. In this chapter, we review how crystal structures can initiate structure-based drug design in general.
Collapse
Affiliation(s)
- J. de Ruyck
- Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576 of the Centre National de la Recherche Scientifique and the University of Lille 50 Avenue de Halley 59658 Villeneuve d'Ascq France
| | - G. Roos
- Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576 of the Centre National de la Recherche Scientifique and the University of Lille 50 Avenue de Halley 59658 Villeneuve d'Ascq France
- Université Libre de Bruxelles (ULB), Structure and Function of Biological Membranes CP 206/2, Boulevard du Triomphe, 1050 Brussels Belgium
| | - E.-M. Krammer
- Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576 of the Centre National de la Recherche Scientifique and the University of Lille 50 Avenue de Halley 59658 Villeneuve d'Ascq France
- Université Libre de Bruxelles (ULB), Structure and Function of Biological Membranes CP 206/2, Boulevard du Triomphe, 1050 Brussels Belgium
| | - M. Prévost
- Université Libre de Bruxelles (ULB), Structure and Function of Biological Membranes CP 206/2, Boulevard du Triomphe, 1050 Brussels Belgium
| | - M. F. Lensink
- Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576 of the Centre National de la Recherche Scientifique and the University of Lille 50 Avenue de Halley 59658 Villeneuve d'Ascq France
| | - J. Bouckaert
- Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576 of the Centre National de la Recherche Scientifique and the University of Lille 50 Avenue de Halley 59658 Villeneuve d'Ascq France
| |
Collapse
|
5
|
Sivignon A, Bouckaert J, Bernard J, Gouin SG, Barnich N. The potential of FimH as a novel therapeutic target for the treatment of Crohn’s disease. Expert Opin Ther Targets 2017; 21:837-847. [DOI: 10.1080/14728222.2017.1363184] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Adeline Sivignon
- M2iSH, UMR 1071 Inserm, INRA USC-2018, Institut Universitaire Technologique, Université Clermont Auvergne, Clermont-Ferrand 63001, France
| | - Julie Bouckaert
- Univ. Lille, CNRS, UMR 8576 – UGSF – Unité de Glycobiologie Structurale et Fonctionnelle, 59000 Lille, France
| | - Julien Bernard
- Université de Lyon, Lyon, France ; INSA-Lyon, Ingénierie des Matériaux Polymères (IMP), Villeurbanne, France ; CNRS, UMR 5223, Ingénierie des Matériaux Polymères, Villeurbanne, France
- INSA-Lyon, IMP, Villeurbanne, France
- UMR 5223, Ingénierie des Matériaux Polymères, CNRS, Villeurbanne, France
| | - Sebastien G. Gouin
- CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques, LUNAM Université, Nantes Cedex 3, France
| | - Nicolas Barnich
- M2iSH, UMR 1071 Inserm, INRA USC-2018, Institut Universitaire Technologique, Université Clermont Auvergne, Clermont-Ferrand 63001, France
| |
Collapse
|
6
|
Touaibia M, Krammer EM, Shiao TC, Yamakawa N, Wang Q, Glinschert A, Papadopoulos A, Mousavifar L, Maes E, Oscarson S, Vergoten G, Lensink MF, Roy R, Bouckaert J. Sites for Dynamic Protein-Carbohydrate Interactions of O- and C-Linked Mannosides on the E. coli FimH Adhesin. Molecules 2017; 22:molecules22071101. [PMID: 28671638 PMCID: PMC6152123 DOI: 10.3390/molecules22071101] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Revised: 06/25/2017] [Accepted: 06/28/2017] [Indexed: 01/28/2023] Open
Abstract
Antagonists of the Escherichia coli type-1 fimbrial adhesin FimH are recognized as attractive alternatives for antibiotic therapies and prophylaxes against acute and recurrent bacterial infections. In this study α-d-mannopyranosides O- or C-linked with an alkyl, alkene, alkyne, thioalkyl, amide, or sulfonamide were investigated to fit a hydrophobic substituent with up to two aryl groups within the tyrosine gate emerging from the mannose-binding pocket of FimH. The results were summarized into a set of structure-activity relationships to be used in FimH-targeted inhibitor design: alkene linkers gave an improved affinity and inhibitory potential, because of their relative flexibility combined with a favourable interaction with isoleucine-52 located in the middle of the tyrosine gate. Of particular interest is a C-linked mannoside, alkene-linked to an ortho-substituted biphenyl that has an affinity similar to its O-mannosidic analog but superior to its para-substituted analog. Docking of its high-resolution NMR solution structure to the FimH adhesin indicated that its ultimate, ortho-placed phenyl ring is able to interact with isoleucine-13, located in the clamp loop that undergoes conformational changes under shear force exerted on the bacteria. Molecular dynamics simulations confirmed that a subpopulation of the C-mannoside conformers is able to interact in this secondary binding site of FimH.
Collapse
Affiliation(s)
- Mohamed Touaibia
- Pharmaqam, Department of Chemistry, Université du Québec à Montréal, P. O. Box 8888, Succ. Centre-ville, Montréal, QC H3C 3P8, Canada.
- Department of Chemistry and Biochemistry, Université de Moncton, Moncton, NB E1A 3E9, Canada.
| | - Eva-Maria Krammer
- Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), UMR8576 du CNRS, Université de Lille, F-59000 Lille, France.
| | - Tze C Shiao
- Pharmaqam, Department of Chemistry, Université du Québec à Montréal, P. O. Box 8888, Succ. Centre-ville, Montréal, QC H3C 3P8, Canada.
| | - Nao Yamakawa
- Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), UMR8576 du CNRS, Université de Lille, F-59000 Lille, France.
| | - Qingan Wang
- Pharmaqam, Department of Chemistry, Université du Québec à Montréal, P. O. Box 8888, Succ. Centre-ville, Montréal, QC H3C 3P8, Canada.
| | - Anja Glinschert
- Center for Synthesis and Chemical Biology (CSCB), University College Dublin, Belfield, Dublin 4, Ireland.
| | - Alex Papadopoulos
- Pharmaqam, Department of Chemistry, Université du Québec à Montréal, P. O. Box 8888, Succ. Centre-ville, Montréal, QC H3C 3P8, Canada.
| | - Leila Mousavifar
- Pharmaqam, Department of Chemistry, Université du Québec à Montréal, P. O. Box 8888, Succ. Centre-ville, Montréal, QC H3C 3P8, Canada.
| | - Emmanuel Maes
- Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), UMR8576 du CNRS, Université de Lille, F-59000 Lille, France.
| | - Stefan Oscarson
- Center for Synthesis and Chemical Biology (CSCB), University College Dublin, Belfield, Dublin 4, Ireland.
| | - Gerard Vergoten
- Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), UMR8576 du CNRS, Université de Lille, F-59000 Lille, France.
| | - Marc F Lensink
- Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), UMR8576 du CNRS, Université de Lille, F-59000 Lille, France.
| | - René Roy
- Pharmaqam, Department of Chemistry, Université du Québec à Montréal, P. O. Box 8888, Succ. Centre-ville, Montréal, QC H3C 3P8, Canada.
| | - Julie Bouckaert
- Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), UMR8576 du CNRS, Université de Lille, F-59000 Lille, France.
| |
Collapse
|
7
|
Alvarez Dorta D, Chalopin T, Sivignon A, de Ruyck J, Dumych TI, Bilyy RO, Deniaud D, Barnich N, Bouckaert J, Gouin SG. Physiochemical Tuning of Potent Escherichia coli Anti-Adhesives by Microencapsulation and Methylene Homologation. ChemMedChem 2017; 12:986-998. [PMID: 28257558 DOI: 10.1002/cmdc.201700061] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Indexed: 11/06/2022]
Abstract
Thiazolylaminomannosides (TazMan) are FimH antagonists with anti-adhesive potential against adherent-invasive Escherichia coli (AIEC) promoting gut inflammation in patients with Crohn's disease. The lead TazMan is highly potent in vitro, but shows limited in vivo efficiency, probably due to low pH stability and water solubility. We recently developed a second generation of stable TazMan, but the anti-adhesive effect was lower than the first. Herein we report a co-crystal structure of the lead TazMan in FimH, revealing that the anomeric NH group and the second thiazole moiety provide a positive hydrogen bonding interaction with a trapped water molecule, and π-stacking with Tyr48 of FimH, respectively. Consequently, we developed NeoTazMan homologated with a methylene group for low-pH and mannosidase stability with a conserved NH group and bearing various heterocyclic aglycones. Microencapsulation of the lead NeoTazMan in γ-cyclodextrin dramatically improved water solubility without disrupting the affinity for FimH or the anti-adhesive effect against AIEC isolated from patients with Crohn's disease.
Collapse
Affiliation(s)
- Dimitri Alvarez Dorta
- LUNAM Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques, 2 rue de la Houssinière, BP 92208, 44322, Nantes Cedex 3, France
| | - Thibaut Chalopin
- LUNAM Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques, 2 rue de la Houssinière, BP 92208, 44322, Nantes Cedex 3, France
| | - Adeline Sivignon
- Université Clermont Auvergne, Inserm U1071, M2iSH, USC-INRA 2018, 63000, Clermont-Ferrand, France
| | - Jérôme de Ruyck
- Université Lille, Unité de Glycobiologie Structurale et Fonctionnelle, CNRS UMR8576 UGSF, FRABio FR3688, 59000, Lille, France
| | - Tetiana I Dumych
- Danylo Halytsky Lviv National Medical University, Pekarska Str. 69, 79010, Lviv, Ukraine
| | - Rostyslav O Bilyy
- Danylo Halytsky Lviv National Medical University, Pekarska Str. 69, 79010, Lviv, Ukraine
| | - David Deniaud
- LUNAM Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques, 2 rue de la Houssinière, BP 92208, 44322, Nantes Cedex 3, France
| | - Nicolas Barnich
- Université Clermont Auvergne, Inserm U1071, M2iSH, USC-INRA 2018, 63000, Clermont-Ferrand, France
| | - Julie Bouckaert
- Université Lille, Unité de Glycobiologie Structurale et Fonctionnelle, CNRS UMR8576 UGSF, FRABio FR3688, 59000, Lille, France
| | - Sébastien G Gouin
- LUNAM Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques, 2 rue de la Houssinière, BP 92208, 44322, Nantes Cedex 3, France
| |
Collapse
|
8
|
Rabbani S, Krammer EM, Roos G, Zalewski A, Preston R, Eid S, Zihlmann P, Prévost M, Lensink MF, Thompson A, Ernst B, Bouckaert J. Mutation of Tyr137 of the universal Escherichia coli fimbrial adhesin FimH relaxes the tyrosine gate prior to mannose binding. IUCRJ 2017; 4:7-23. [PMID: 28250938 PMCID: PMC5331462 DOI: 10.1107/s2052252516016675] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Accepted: 10/18/2016] [Indexed: 05/08/2023]
Abstract
The most prevalent diseases manifested by Escherichia coli are acute and recurrent bladder infections and chronic inflammatory bowel diseases such as Crohn's disease. E. coli clinical isolates express the FimH adhesin, which consists of a mannose-specific lectin domain connected via a pilin domain to the tip of type 1 pili. Although the isolated FimH lectin domain has affinities in the nanomolar range for all high-mannosidic glycans, differentiation between these glycans is based on their capacity to form predominantly hydrophobic interactions within the tyrosine gate at the entrance to the binding pocket. In this study, novel crystal structures of tyrosine-gate mutants of FimH, ligand-free or in complex with heptyl α-d-O-mannopyranoside or 4-biphenyl α-d-O-mannopyranoside, are combined with quantum-mechanical calculations and molecular-dynamics simulations. In the Y48A FimH crystal structure, a large increase in the dynamics of the alkyl chain of heptyl α-d-O-mannopyranoside attempts to compensate for the absence of the aromatic ring; however, the highly energetic and stringent mannose-binding pocket of wild-type FimH is largely maintained. The Y137A mutation, on the other hand, is the most detrimental to FimH affinity and specificity: (i) in the absence of ligand the FimH C-terminal residue Thr158 intrudes into the mannose-binding pocket and (ii) ethylenediaminetetraacetic acid interacts strongly with Glu50, Thr53 and Asn136, in spite of multiple dialysis and purification steps. Upon mutation, pre-ligand-binding relaxation of the backbone dihedral angles at position 137 in the tyrosine gate and their coupling to Tyr48 via the interiorly located Ile52 form the basis of the loss of affinity of the FimH adhesin in the Y137A mutant.
Collapse
Affiliation(s)
- Said Rabbani
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50-70, CH-4056 Basel, Switzerland
| | - Eva-Maria Krammer
- University of Lille, CNRS UMR8576 UGSF (Unité de Glycobiologie Structurale et Fonctionnelle), 59000 Lille, France
- Structure et Fonction des Membranes Biologiques, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - Goedele Roos
- University of Lille, CNRS UMR8576 UGSF (Unité de Glycobiologie Structurale et Fonctionnelle), 59000 Lille, France
- Structure et Fonction des Membranes Biologiques, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - Adam Zalewski
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50-70, CH-4056 Basel, Switzerland
| | - Roland Preston
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50-70, CH-4056 Basel, Switzerland
| | - Sameh Eid
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50-70, CH-4056 Basel, Switzerland
| | - Pascal Zihlmann
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50-70, CH-4056 Basel, Switzerland
| | - Martine Prévost
- Structure et Fonction des Membranes Biologiques, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - Marc F. Lensink
- University of Lille, CNRS UMR8576 UGSF (Unité de Glycobiologie Structurale et Fonctionnelle), 59000 Lille, France
| | - Andrew Thompson
- Synchrotron SOLEIL, l’Orme de Merisiers, Saint-Aubin BP48, Gif-sur-Yvette CEDEX, France
| | - Beat Ernst
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50-70, CH-4056 Basel, Switzerland
| | - Julie Bouckaert
- University of Lille, CNRS UMR8576 UGSF (Unité de Glycobiologie Structurale et Fonctionnelle), 59000 Lille, France
| |
Collapse
|
9
|
Alvarez Dorta D, Sivignon A, Chalopin T, Dumych TI, Roos G, Bilyy RO, Deniaud D, Krammer EM, de Ruyck J, Lensink MF, Bouckaert J, Barnich N, Gouin SG. The Antiadhesive Strategy in Crohn's Disease: Orally Active Mannosides to Decolonize Pathogenic Escherichia coli from the Gut. Chembiochem 2016; 17:936-52. [PMID: 26946458 DOI: 10.1002/cbic.201600018] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2016] [Indexed: 11/07/2022]
Abstract
Blocking the adherence of bacteria to cells is an attractive complementary approach to current antibiotic treatments, which are faced with increasing resistance. This strategy has been particularly studied in the context of urinary tract infections (UTIs), in which the adhesion of pathogenic Escherichia coli strains to uroepithelial cells is prevented by blocking the FimH adhesin expressed at the tips of bacteria organelles called fimbriae. Recently, we extended the antiadhesive concept, showing that potent FimH antagonists can block the attachment of adherent-invasive E. coli (AIEC) colonizing the intestinal mucosa of patients with Crohn's disease (CD). In this work, we designed a small library of analogues of heptyl mannoside (HM), a previously identified nanomolar FimH inhibitor, but one that displays poor antiadhesive effects in vivo. The anomeric oxygen atom was replaced by a sulfur or a methylene group to prevent hydrolysis by intestinal glycosidases, and chemical groups were attached at the end of the alkyl tail. Importantly, a lead compound was shown to reduce AIEC levels in the feces and in the colonic and ileal mucosa after oral administration (10 mg kg(-1) ) in a transgenic mouse model of CD. The compound showed a low bioavailability, preferable in this instance, thus suggesting the possibility of setting up an innovative antiadhesive therapy, based on the water-soluble and non-cytotoxic FimH antagonists developed here, for the CD subpopulation in which AIEC plays a key role.
Collapse
Affiliation(s)
- Dimitri Alvarez Dorta
- LUNAM Université, CEISAM, Chimie et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, 2, rue de la Houssinière, BP 92208, 44322, Nantes Cedex 3, France
| | - Adeline Sivignon
- Clermont Université, UMR 1071 Inserm/Université d'Auvergne, 63000, Clermont-Ferrand, France
| | - Thibaut Chalopin
- LUNAM Université, CEISAM, Chimie et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, 2, rue de la Houssinière, BP 92208, 44322, Nantes Cedex 3, France
| | - Tetiana I Dumych
- Univ. Lille, CNRS, UMR 8576-UGSF-Unité de Glycobiologie Structurale et Fonctionnelle, 59000, Lille, France
| | - Goedele Roos
- Structure and Function of Biological Membranes, Université Libre de Bruxelles, Boulevard du Triomphe, 1050, Brussels, Belgium
| | - Rostyslav O Bilyy
- Danylo Halytsky Lviv National Medical University, Pekarska Str. 69, 79010, Lviv, Ukraine
| | - David Deniaud
- LUNAM Université, CEISAM, Chimie et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, 2, rue de la Houssinière, BP 92208, 44322, Nantes Cedex 3, France
| | - Eva-Maria Krammer
- Univ. Lille, CNRS, UMR 8576-UGSF-Unité de Glycobiologie Structurale et Fonctionnelle, 59000, Lille, France
| | - Jérome de Ruyck
- Univ. Lille, CNRS, UMR 8576-UGSF-Unité de Glycobiologie Structurale et Fonctionnelle, 59000, Lille, France
| | - Marc F Lensink
- Univ. Lille, CNRS, UMR 8576-UGSF-Unité de Glycobiologie Structurale et Fonctionnelle, 59000, Lille, France
| | - Julie Bouckaert
- Univ. Lille, CNRS, UMR 8576-UGSF-Unité de Glycobiologie Structurale et Fonctionnelle, 59000, Lille, France
| | - Nicolas Barnich
- Clermont Université, UMR 1071 Inserm/Université d'Auvergne, 63000, Clermont-Ferrand, France
| | - Sébastien G Gouin
- LUNAM Université, CEISAM, Chimie et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, 2, rue de la Houssinière, BP 92208, 44322, Nantes Cedex 3, France.
| |
Collapse
|
10
|
Sauer MM, Jakob RP, Eras J, Baday S, Eriş D, Navarra G, Bernèche S, Ernst B, Maier T, Glockshuber R. Catch-bond mechanism of the bacterial adhesin FimH. Nat Commun 2016; 7:10738. [PMID: 26948702 PMCID: PMC4786642 DOI: 10.1038/ncomms10738] [Citation(s) in RCA: 144] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Accepted: 01/13/2016] [Indexed: 01/12/2023] Open
Abstract
Ligand–receptor interactions that are reinforced by mechanical stress, so-called catch-bonds, play a major role in cell–cell adhesion. They critically contribute to widespread urinary tract infections by pathogenic Escherichia coli strains. These pathogens attach to host epithelia via the adhesin FimH, a two-domain protein at the tip of type I pili recognizing terminal mannoses on epithelial glycoproteins. Here we establish peptide-complemented FimH as a model system for fimbrial FimH function. We reveal a three-state mechanism of FimH catch-bond formation based on crystal structures of all states, kinetic analysis of ligand interaction and molecular dynamics simulations. In the absence of tensile force, the FimH pilin domain allosterically accelerates spontaneous ligand dissociation from the FimH lectin domain by 100,000-fold, resulting in weak affinity. Separation of the FimH domains under stress abolishes allosteric interplay and increases the affinity of the lectin domain. Cell tracking demonstrates that rapid ligand dissociation from FimH supports motility of piliated E. coli on mannosylated surfaces in the absence of shear force. Catch bonds have a role in bacterial adhesion and infection by uropathogenic E. coli. Here, the authors report crystal structures, molecular dynamics simulations, ligand binding analysis and cell tracking to characterise the catch bond interaction between the adhesin FimH and carbohydrate receptors.
Collapse
Affiliation(s)
- Maximilian M Sauer
- Institute of Molecular Biology and Biophysics, Department of Biology, ETH, Zurich, Otto-Stern-Weg 5, 8093 Zurich, Switzerland
| | - Roman P Jakob
- Biozentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland
| | - Jonathan Eras
- Institute of Molecular Biology and Biophysics, Department of Biology, ETH, Zurich, Otto-Stern-Weg 5, 8093 Zurich, Switzerland
| | - Sefer Baday
- Biozentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland.,SIB Swiss Institute of Bioinformatics, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland
| | - Deniz Eriş
- Institute of Molecular Pharmacy, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Giulio Navarra
- Institute of Molecular Pharmacy, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Simon Bernèche
- Biozentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland.,SIB Swiss Institute of Bioinformatics, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland
| | - Beat Ernst
- Institute of Molecular Pharmacy, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Timm Maier
- Biozentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland
| | - Rudi Glockshuber
- Institute of Molecular Biology and Biophysics, Department of Biology, ETH, Zurich, Otto-Stern-Weg 5, 8093 Zurich, Switzerland
| |
Collapse
|
11
|
Mydock-McGrane LK, Cusumano ZT, Janetka JW. Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn’s disease. Expert Opin Ther Pat 2016; 26:175-97. [DOI: 10.1517/13543776.2016.1131266] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
12
|
Development of Heptylmannoside-Based Glycoconjugate Antiadhesive Compounds against Adherent-Invasive Escherichia coli Bacteria Associated with Crohn's Disease. mBio 2015; 6:e01298-15. [PMID: 26578673 PMCID: PMC4659459 DOI: 10.1128/mbio.01298-15] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The ileal lesions of Crohn’s disease (CD) patients are colonized by adherent-invasive Escherichia coli (AIEC) bacteria. These bacteria adhere to mannose residues expressed by CEACAM6 on host cells in a type 1 pilus-dependent manner. In this study, we investigated different antagonists of FimH, the adhesin of type 1 pili, for their ability to block AIEC adhesion to intestinal epithelial cells (IEC). Monovalent and multivalent derivatives of n-heptyl α-d-mannoside (HM), a nanomolar antagonist of FimH, were tested in vitro in IEC infected with the AIEC LF82 strain and in vivo by oral administration to CEACAM6-expressing mice infected with LF82 bacteria. In vitro, multivalent derivatives were more potent than the monovalent derivatives, with a gain of efficacy superior to their valencies, probably owing to their ability to form bacterial aggregates. Of note, HM and the multi-HM glycoconjugates exhibited lower efficacy in vivo in decreasing LF82 gut colonization. Interestingly, HM analogues functionalized with an isopropylamide (1A-HM) or β-cyclodextrin pharmacophore at the end of the heptyl tail (1CD-HM) exerted beneficial effects in vivo. These two compounds strongly decreased the amount of LF82 bacteria in the feces of mice and that of bacteria associated with the gut mucosa when administered orally at a dose of 10 mg/kg of body weight after infection. Importantly, signs of colitis and intestinal inflammation induced by LF82 infection were also prevented. These results highlight the potential of the antiadhesive compounds to treat CD patients abnormally colonized by AIEC bacteria and point to an alternative to the current approach focusing on blocking proinflammatory mediators. Current treatments for Crohn’s disease (CD), including immunosuppressive agents, anti-tumor necrosis factor alpha (anti-TNF-α) and anti-integrin antibodies, focus on the symptoms but not on the cause of the disease. Adherent-invasive Escherichia coli (AIEC) bacteria abnormally colonize the ileal mucosa of CD patients via the interaction of the mannose-specific adhesin FimH of type 1 pili with CEACAM6 mannosylated proteins expressed on the epithelial cell surface. Thus, we decided to develop an antiadhesive strategy based on synthetic FimH antagonists specifically targeting AIEC bacteria that would decrease intestinal inflammation. Heptylmannoside (HM)-based glycocompounds strongly inhibit AIEC adhesion to intestinal epithelial cells in vitro. The antiadhesive effect of two of these compounds of relatively simple chemical structure was also observed in vivo in AIEC-infected CEACAM6-expressing mice and was associated with a reduction in the signs of colitis. These results suggest a new therapeutic approach for CD patients colonized by AIEC bacteria, based on the development of synthetic FimH antagonists.
Collapse
|